48 assets in B-Cell Neoplasm

Therapeutic assets addressing B-Cell Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide B-Cell Neoplasm	University Hospital, Basel, Switzerland	P2	BB (66)
Zanubrutinib B-Cell Neoplasm	Curis, Inc.	P2	BB (66)
Adriamycin B-Cell Neoplasm	Curis, Inc.	P2	BB (65)
Prednisone B-Cell Neoplasm	Curis, Inc.	P2	BB (65)
Rituximab B-Cell Neoplasm	Curis, Inc.	P2	BB (64)
Lenalidomide B-Cell Neoplasm	M.D. Anderson Cancer Center	P2	B (60)
Obinutuzumab B-Cell Neoplasm	BeOne Medicines	P1/2	B (60)
Acalabrutinib B-Cell Neoplasm	AstraZeneca	P1/2	B (57)
(+)-Vincristine B-Cell Neoplasm	National Cancer Institute (NCI)	P1/2	CCC (55)
Emavusertib B-Cell Neoplasm	Curis, Inc.	P2	CCC (53)
Ibrutinib B-Cell Neoplasm	Academic and Community Cancer Research United	P2	CCC (53)
Ruxolitinib B-Cell Neoplasm	Incyte Corporation	P2	CCC (53)
Zamtocabtagene Autoleucel B-Cell Neoplasm	Miltenyi Biomedicine GmbH	P2	CCC (53)
Etoposide B-Cell Neoplasm	National Cancer Institute (NCI)	P1/2	CCC (52)
Fludarabine B-Cell Neoplasm	Han weidong	P1/2	CCC (52)
Parsaclisib B-Cell Neoplasm	Incyte Corporation	P2	CCC (52)
Anti-Cd19 Autologous Car-T Cell Infusion B-Cell Neoplasm	920th Hospital of Joint Logistics Support Force of People's Liberation Army of China	P1/2	CCC (48)
car2219-t cells B-Cell Neoplasm	Affiliated Hospital to Academy of Military Medical Sciences	P1/2	CCC (48)
cd19/cd20 dual-car-t cells B-Cell Neoplasm	Han weidong	P1/2	CCC (48)
Bgb-16673 B-Cell Neoplasm	BeOne Medicines	P1/2	CC (47)
cd22 car-transduced t cells B-Cell Neoplasm	Sheba Medical Center	P1/2	CC (47)
ctx112 B-Cell Neoplasm	CRISPR Therapeutics AG	P1/2	CC (47)
Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,461-Alanine,462-Alanine,556-Glycine,581-Cysteine,593-Tryptophan), Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 Vh-Ch1 Fragment) Fusion Protein With Peptide (Synthetic 10-Amino Acid Linker) Fusion Protein With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Heavy Chain Vl(.Lambda.)-Ch1-Ch2-Ch3), (222->219''')-Disulfide With Immunoglobulin Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine)) And (447->232'')-Disulfide With Immunoglobulin Anti-(Human Cd3 Antigen .Epsilon.-Chain) (Human-Mus Musculus Monoclonal Rg6026 Light Chain Vh-Cl(.Kappa.)), (453->228'), (456->231'), (581->351')-Tris(Disulfide) With Immunoglobulin G1 (149-Glutamic Acid,215-Glutamic Acid,236-Alanine,237-Alanine,331-Glycine,351-Cysteine,368-Serine,370-Alanine,409-Valine) Anti-(Human Cd20 Antigen) (Human-Mus Musculus Monoclonal Rg6026 .Gamma.1-Chain) Disulfide With Human-Mus Musculus Monoclonal Rg6026 .Kappa.-Chain (128-Arginine,129-Lysine) B-Cell Neoplasm	BeOne Medicines	P1/2	CC (47)
Itacitinib B-Cell Neoplasm	Incyte Corporation	P2	CC (47)
Mosunetuzumab B-Cell Neoplasm	BeOne Medicines	P1/2	CC (47)
Shb-02-Cd19 B-Cell Neoplasm	Sheba Medical Center	P1/2	CC (47)
Sonrotoclax B-Cell Neoplasm	BeOne Medicines	P1/2	CC (47)
Pacritinib B-Cell Neoplasm	Shayna Sarosiek, MD	P2	CC (46)
4SCAR123 B-Cell Neoplasm	Shenzhen Geno-Immune Medical Institute	P1/2	CC (45)
4SCAR20 B-Cell Neoplasm	Shenzhen Geno-Immune Medical Institute	P1/2	CC (45)
4SCAR22 B-Cell Neoplasm	Shenzhen Geno-Immune Medical Institute	P1/2	CC (45)
4SCAR30 B-Cell Neoplasm	Shenzhen Geno-Immune Medical Institute	P1/2	CC (45)
4SCAR38 B-Cell Neoplasm	Shenzhen Geno-Immune Medical Institute	P1/2	CC (45)
4SCAR70 B-Cell Neoplasm	Shenzhen Geno-Immune Medical Institute	P1/2	CC (45)
azd5492 B-Cell Neoplasm	AstraZeneca	P1/2	CC (45)
Therapeutic 4Scar19 Cells B-Cell Neoplasm	Shenzhen Geno-Immune Medical Institute	P1/2	CC (45)
Abbv-525 B-Cell Neoplasm	AbbVie	P1	CC (43)
Cart-19 Cells B-Cell Neoplasm	Fundamenta Therapeutics, Ltd.	P1	CC (43)
Docirbrutinib B-Cell Neoplasm	Carna Biosciences, Inc.	P1	CC (43)
Jwcar201 B-Cell Neoplasm	RenJi Hospital	P1	CC (43)
Pomalidomide B-Cell Neoplasm	National Cancer Institute (NCI)	P1	CC (43)
Thiscart22 Cells B-Cell Neoplasm	Fundamenta Therapeutics, Ltd.	P1	CC (43)
sys6005 B-Cell Neoplasm	CSPC Megalith Biopharmaceutical Co.,Ltd.	P1	CC (41)
tt-01488 B-Cell Neoplasm	TransThera Sciences (Nanjing), Inc.	P1	CC (41)
ac676 B-Cell Neoplasm	Accutar Biotechnology Inc	P1	NR ()
Cnty-101 B-Cell Neoplasm	Century Therapeutics, Inc.	P1	NR ()
exs73565 B-Cell Neoplasm	Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.	P1	NR ()
U96 (lentiviral vector) B-Cell Neoplasm	The First Affiliated Hospital of Soochow University	P1	NR ()